Combined Entity Aims to Revolutionize Chronic Skin Disease Treatment with Cutting-Edge Antibodies
ARCA biopharma (ABIO) and Oruka Therapeutics have finalized a landmark agreement to merge, heralding the formation of a company focused on advancing innovative biologics for chronic skin diseases. The merger, an all-stock transaction, underscores a commitment to redefine the standard of care for patients with conditions like plaque psoriasis.
Oruka, the brainchild of assets from Paragon Therapeutics, is poised to lead the charge with its pipeline of potentially best-in-class biologics, including ORKA-001 and ORKA-002. These antibodies, targeting IL-23p19 and IL-17A/F, respectively, hold promise for transforming treatment paradigms. With a pre-closing private financing of approximately $275 million secured, the newly formed entity plans to drive operations and clinical advancements through 2027.
Dr. Lawrence Klein, CEO of Oruka, expressed optimism about the merger, emphasizing the company’s mission to provide freedom from chronic skin diseases. Backed by a consortium of healthcare investors, including Fairmount and Venrock Healthcare Capital Partners, the merger positions Oruka for substantial growth and innovation in the dermatology space.
The scientific foundation for Oruka’s groundbreaking work is rooted in the expertise of Dr. Andrew Blauvelt, chair of Oruka’s Scientific Advisory Board and a renowned figure in psoriasis research. The company’s lead programs, engineered for extended dosing intervals and heightened efficacy, are slated to enter clinical trials in 2025, offering hope for significant advancements in patient care.
Robert E. Conway, Chairman of ARCA’s Board of Directors, underscored the merger’s potential for value creation, signaling a strategic move aligned with ARCA’s long-term objectives.
Pending stockholder approvals and regulatory clearance, the combined entity, to be named Oruka Therapeutics, Inc., is slated to commence operations in the third quarter of 2024. Led by Dr. Lawrence Klein, the new company will embark on a transformative journey to revolutionize the treatment landscape for chronic skin diseases, bringing hope and healing to millions worldwide.
Read original press release:here
You might like this article:Silver Lake Acquires Endeavor at $13 Billion, Setting a New Industry Standard
